Clinical trials: Rivaroxaban
Venous Thromboembolism
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events.
- Trial name
- EINSTEINJr (NCT02309411)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 29 sites in United States, Australia and 13 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Pulmonary Embolism, Venous Thrombosis
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
The trial is an open-label, randomized, trial examining novel biomarkers of thrombosis in patients managed with rivaroxaban vs. standard care following treatment of pulmonary embolism (PE) with catheter-guided alteplase.
- Trial name
- XENITH (NCT02506985)
- Testing
- rivaroxaban, warfarin
- Volunteers
- 10 people
- Sponsor
- Susan Smyth
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Atrial Fibrillation
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels.
- Trial name
- RIVA-DM (NCT04509193)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- United States
- Volunteers
- 116,049 people
- Sponsor
- Bayer
Biological Availability
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT01853800
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Atrial Fibrillation
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in…
- Trial name
- NCT04234698
- Where
- Colombia
- Volunteers
- 2,076 people
- Sponsor
- Pfizer
Deep Vein Thrombosis, Chronic Portal Vein Thrombosis
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the recurrence of thromboembolic event compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia.
- Trial name
- RIPORT (NCT02555111)
- Testing
- Xarelto
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Atrial Fibrillation
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs…
- Trial name
- NCT03462446
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists (VKAs)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel…
- Trial name
- RITMUS-AF (NCT04174859)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Italy
- Volunteers
- 812 people
- Sponsor
- Bayer
Atrial Fibrillation
GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence
In atrial fibrillation patients,anticoagulant therapy with warfarin has an excellent stroke preventive. Meantime,Warfarin may also increase the risk of hemorrhagic events.
- Trial name
- GENeRAL (NCT02633982)
- Where
- Japan
- Volunteers
- 5,000 people
- Sponsor
- Japan Cardiovascular Research Foundation
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Coronary Artery Disease
Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease
Coronary artery disease (CAD) is a manifestation of systemic atherosclerosis for which single antiplatelet therapy (SAPT) is indicated if patients are stable.
- Trial name
- DUALCAD (NCT05210725)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Registry of Patients Prescribed Anticoagulation
The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism…
- Trial name
- STAGPOR (NCT03504007)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Mayo Clinic
Peripheral Arterial Disease
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
Assessing the outcomes of using Rivaroxaban plus Aspirin in patients with Lower Extremity Peripheral Arterial Disease after Endovascular Revascularization
- Trial name
- NCT05308030
- Testing
- Rivaroxaban and Aspirin
- Volunteers
- 100 people
- Sponsor
- Assiut University
Healthy
Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)
Rivaroxaban (RXA; brand name Xarelto®) is an oral direct factor Xa inhibitor that is applied for prophylaxis of venous thromboembolism after major orthopedic surgery.
- Trial name
- RivaMoS2 (NCT01710267)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD
Healthy Subjects
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
The study was designed as a single-site, randomized, open-label, four-period complete and replicate crossover. A single oral dose of 20 mg rivaroxaban tablet (test) and Xarelto®(reference) was given to the 72 healthy Chinese…
- Trial name
- NCT04424381
- Testing
- Rivaroxaban 20 MG Oral Tablet [Xarelto], Rivaroxaban 20 MG Oral Tablet
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Atrial Fibrillation, Intracerebral Hemorrhage
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
Atrial fibrillation (AF) is the most common form of irregular heart rhythm. In people with AF, blood clots often form in the heart, which can travel to the brain.
- Trial name
- PRESTIGE-AF (NCT03996772)
- Testing
- Apixaban Oral Tablet, Dabigatran, Edoxaban Tablets
- Where
- 64 sites in Austria, France and 4 more
- Volunteers
- 319 people
- Sponsor
- Imperial College London
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Radial Artery Occlusion
Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization
The purpose of the RIVA-RAO study is to determine whether the use of Rivaroxaban is an effective treatment of radial artery occlusion (RAO) after cardiac catheterization (both angiography and PCI).
- Trial name
- RIVA-RAO (NCT06812455)
- Testing
- Rivaroxaban
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- AHEPA University Hospital